Lilly’s Prevail Signs Gene Editing Collaboration with Scribe Therapeutics for Neurological Diseases

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)

Published: 22 May-2023

DOI: 10.3833/pdr.v2023.i5.2786     ISSN: 1756-7874

Section: Licensing



Prevail Therapeutics, a subsidiary of Lilly, has entered into a collaboration with Scribe Therapeutics to leverage the latter’s CRISPR technology to develop in vivo therapies for serious neurological and neuromuscular diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details